Gilead Sciences Inc (GILD)
90.19
+0.43
(+0.48%)
USD |
NASDAQ |
Nov 22, 16:00
90.16
-0.03
(-0.03%)
After-Hours: 20:00
Gilead Sciences Revenue (TTM): 28.30B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 28.30B |
| June 30, 2024 | 27.80B |
| March 31, 2024 | 27.45B |
| December 31, 2023 | 27.12B |
| September 30, 2023 | 27.39B |
| June 30, 2023 | 27.38B |
| March 31, 2023 | 27.04B |
| December 31, 2022 | 27.28B |
| September 30, 2022 | 27.14B |
| June 30, 2022 | 27.52B |
| March 31, 2022 | 27.47B |
| December 31, 2021 | 27.30B |
| September 30, 2021 | 27.48B |
| June 30, 2021 | 26.64B |
| March 31, 2021 | 25.56B |
| December 31, 2020 | 24.69B |
| September 30, 2020 | 23.15B |
| June 30, 2020 | 22.17B |
| March 31, 2020 | 22.72B |
| December 31, 2019 | 22.45B |
| September 30, 2019 | 22.36B |
| June 30, 2019 | 22.36B |
| March 31, 2019 | 22.32B |
| December 31, 2018 | 22.13B |
| September 30, 2018 | 22.28B |
| Date | Value |
|---|---|
| June 30, 2018 | 23.20B |
| March 31, 2018 | 24.69B |
| December 31, 2017 | 26.11B |
| September 30, 2017 | 27.48B |
| June 30, 2017 | 28.47B |
| March 31, 2017 | 29.10B |
| December 31, 2016 | 30.39B |
| September 30, 2016 | 31.58B |
| June 30, 2016 | 32.37B |
| March 31, 2016 | 32.84B |
| December 31, 2015 | 32.64B |
| September 30, 2015 | 31.45B |
| June 30, 2015 | 29.19B |
| March 31, 2015 | 27.48B |
| December 31, 2014 | 24.89B |
| September 30, 2014 | 20.70B |
| June 30, 2014 | 17.44B |
| March 31, 2014 | 13.67B |
| December 31, 2013 | 11.20B |
| September 30, 2013 | 10.67B |
| June 30, 2013 | 10.31B |
| March 31, 2013 | 9.951B |
| December 31, 2012 | 9.702B |
| September 30, 2012 | 9.315B |
| June 30, 2012 | 9.010B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
22.17B
Minimum
Jun 2020
28.30B
Maximum
Sep 2024
26.20B
Average
27.21B
Median
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| Merck & Co Inc | 63.17B |
| Pfizer Inc | 59.37B |
| Amgen Inc | 32.53B |
| Vertex Pharmaceuticals Inc | 10.63B |